INT63177

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1996
Last Reported 2010
Negated 9
Speculated 2
Reported most in Body
Documents 71
Total Number 74
Disease Relevance 39.48
Pain Relevance 5.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (HP)
Anatomy Link Frequency
blood 3
plasma 1
tail 1
Joint 1
superior 1
HP (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 45 99.52 Very High Very High Very High
cINOD 37 99.36 Very High Very High Very High
ischemia 22 98.48 Very High Very High Very High
Pain 59 98.16 Very High Very High Very High
Nerve growth factor 16 97.68 Very High Very High Very High
Inflammation 110 97.20 Very High Very High Very High
metalloproteinase 13 97.18 Very High Very High Very High
cva 19 96.80 Very High Very High Very High
Angina 14 95.68 Very High Very High Very High
Opioid 8 95.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypertension 2418 100.00 Very High Very High Very High
Ulcers 23 100.00 Very High Very High Very High
Diabetes Mellitus 668 99.86 Very High Very High Very High
Dyspnea 7 99.84 Very High Very High Very High
Prehypertension 26 99.10 Very High Very High Very High
Coronary Heart Disease 111 98.88 Very High Very High Very High
Cv Unclassified Under Development 22 98.48 Very High Very High Very High
Pain 53 98.16 Very High Very High Very High
Coronary Artery Disease 81 97.48 Very High Very High Very High
Cardiovascular Disease 169 97.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A similar effect was observed for haptoglobin mRNA, used as a control for acute-phase protein expression.
Regulation (effect) of haptoglobin
1) Confidence 0.44 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 10486281 Disease Relevance 0.16 Pain Relevance 0.13
A similar effect was observed for haptoglobin mRNA, used as a control for acute-phase protein expression.
Regulation (control) of haptoglobin
2) Confidence 0.44 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 10486281 Disease Relevance 0.16 Pain Relevance 0.13
Two acute phase proteins, haptoglobin and alpha1 acid-glycoprotein, were not different at any time.
Neg (not) Regulation (different) of haptoglobin
3) Confidence 0.38 Published 2002 Journal J. Dairy Sci. Section Abstract Doc Link 12487452 Disease Relevance 0.07 Pain Relevance 0.07
Our results support the concept 1) the interaction between Hp infection and NSAID on gastro-duodenal ulcerations is antagonistic, 2) the Hp and NSAID are independent risk factors for peptic ulcerations in humans, 3) there is no need for the Hp eradication in NSAID-treated patients, and 4) the rate of ulcer complications (hemorrhage and perforation) remains constant despite the decrease in Hp and ulcer prevalence.
Neg (no) Regulation (need) of Hp associated with ulcers, cinod, cva and infection
4) Confidence 0.36 Published 2002 Journal Med. Sci. Monit. Section Abstract Doc Link 12218957 Disease Relevance 2.34 Pain Relevance 1.09
Previous work showed that the banding process of docking minimally affected mature cows' behavior and physiology, but cutting off the necrotic tail increased haptoglobin.
Regulation (affected) of haptoglobin in tail
5) Confidence 0.33 Published 2002 Journal J. Dairy Sci. Section Abstract Doc Link 12487452 Disease Relevance 0.07 Pain Relevance 0.07
First, preventive anti-oxidants inhibit the formation of free radicals, including SOD, carotenoids, catalase, glutathione peroxidase, transferrin, albumin, and haptoglobin.
Regulation (formation) of haptoglobin
6) Confidence 0.09 Published 2010 Journal Journal of Periodontal & Implant Science Section Body Doc Link PMC2931304 Disease Relevance 0.24 Pain Relevance 0
In subjects with prehypertension, daily intake of both MPH1 and MPH2 did not affect BP.
Neg (not) Regulation (affect) of BP associated with prehypertension and hypertension
7) Confidence 0.07 Published 2010 Journal Nutr J Section Body Doc Link PMC2989300 Disease Relevance 0.94 Pain Relevance 0.09
BP regulation entails complex physiology, and the detailed mechanisms by which VSP inhibitors elevate BP in humans remain undetermined.
Regulation (regulation) of BP
8) Confidence 0.06 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.70 Pain Relevance 0
Notably, this general statement is dependent on the physician's expertise in controlling BP.
Regulation (controlling) of BP
9) Confidence 0.06 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.44 Pain Relevance 0.12
Kinase inhibitor therapy should be reinstituted at the same or lower dose once BP control and titration of antihypertensive agents is achieved to increase the likelihood for tumor control.
Regulation (control) of BP associated with cancer
10) Confidence 0.06 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.46 Pain Relevance 0
SULT4A1 is one of the hSULTs that is most divergent in sequence, and examination of the binding pocket revealed two significant differences that are predicted to affect PAP binding.
Regulation (affect) of binding
11) Confidence 0.05 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1847840 Disease Relevance 0 Pain Relevance 0
Notably, this general statement is dependent on the physician's expertise in controlling BP.
Regulation (controlling) of BP
12) Confidence 0.05 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.44 Pain Relevance 0.12
Upon data analysis, placebo BP values were found to be lower than baseline values at the time of screening.
Regulation (values) of BP associated with hypertension
13) Confidence 0.04 Published 2010 Journal Nutr J Section Body Doc Link PMC2989300 Disease Relevance 1.09 Pain Relevance 0
Thus, change in BP is necessarily dependent upon change in cardiac and vascular function that produces change in CO and/or SVR.
Regulation (change) of BP in SVR
14) Confidence 0.04 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993997 Disease Relevance 0.43 Pain Relevance 0
Compared with those allocated to the atenolol-based regimen, BP values were lower throughout the trial in those allocated to the amlodipine-based regimen.
Regulation (values) of BP
15) Confidence 0.04 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993997 Disease Relevance 0.47 Pain Relevance 0
Several different reasons have been identified to explain the poor extent of BP control, including: 1) inadequate compliance to treatment; 2) insufficient use of drug combinations; and 3) the high proportion of patients who withdraw from treatment because of incomplete BP control (Ambrosioni et al 2000).
Regulation (control) of BP
16) Confidence 0.03 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994025 Disease Relevance 0.42 Pain Relevance 0
Before beginning VSP inhibitor therapy, obtain objective evidence of improving BP control and plan to continue titration of the antihypertensive agent to the numerical goal as VSP inhibitor therapy begins.
Regulation (control) of BP
17) Confidence 0.03 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.21 Pain Relevance 0
Nevertheless, control of BP is important for patients receiving VSP inhibitor therapy for the following five reasons:Serious adverse events have been associated with unmanaged hypertension (1–3,5,34), and these could be prevented with control of BP before and early in the course of VSP inhibitor therapy.These agents can cause dramatic increases in BP from pretreatment measurements (as high as 29 mmHg systolic and 27 mmHg diastolic in one prospective clinical investigation) (35) during the first week of treatment (35,36), and currently, it cannot be predicted which patients will have this magnitude of BP elevation.Although minimalist approaches to hypertension for patients with incurable disease might be favored in certain circumstances, management of comorbidities, including hypertension, could improve overall survival.
Regulation (control) of BP associated with hypertension and disease
18) Confidence 0.03 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.65 Pain Relevance 0
The authors concluded that aliskiren, through inhibition of renin, was an effective and safe orally active BP-lowering drug.66
Regulation (effective) of BP
19) Confidence 0.02 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.36 Pain Relevance 0
All subjects were normotensive upon enrollment, and no changes in BP or heart rate were observed.
Neg (no) Regulation (changes) of BP in heart
20) Confidence 0.02 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.69 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox